Effects of OKY-046, a selective thromboxane A2 synthetase inhibitor, on ventricular arrhythmias and prostaglandins during coronary artery ligation and reperfusion in anesthetized dogs.
Effects of OKY-046, a selective thromboxane synthetase inhibitor, on ischemia-induced ventricular arrhythmias were investigated in anesthetized dogs. OKY-046 (30 mg/kg, intravenously) decreased ventricular arrhythmias significantly both during 30 min of coronary artery ligation and subsequent reperfusion, which corresponded with a significant reduction of thromboxane concentration, suggesting that thromboxane released during ligation is an important factor in the development of ventricular arrhythmias. Inhibition of thromboxane synthesis with OKY-046 might be useful for the prevention of ischemia-induced ventricular arrhythmias.
Ogura
T
T
2nd Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Watanabe
I
I
Saito
T
T
Saito
S
S
Ozawa
Y
Y
Hatano
M
M
D000179:Acrylates / Q000494:pharmacology*; D000758:Anesthesia; D000818:Animals; D000889:Anti-Arrhythmia Agents; D003331:Coronary Vessels / Q000502:physiology*; D004285:Dogs; D008689:Methacrylates / Q000494:pharmacology*; D010477:Perfusion; D011448:Prostaglandin Antagonists; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D013931:Thromboxanes / Q000378:metabolism
D000179:Acrylates; D000889:Anti-Arrhythmia Agents; D008689:Methacrylates; D011448:Prostaglandin Antagonists; D013931:Thromboxanes; D013930:Thromboxane-A Synthase; C034364:ozagrel